January 25, 2018 / 3:05 PM / in a month

BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority

Jan 25 (Reuters) - Celgene Corp:

* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY

* CELGENE CEO SAYS POSITIONED TO LAUNCH TWO CAR-T THERAPIES IN BLOOD CANCERS IN NEXT 3 YEARS

* CELGENE SEES $1 BILLION SALES POTENTIAL FOR FEDRATINIB IN MYELOFIBROSIS, MID-2018 REGULATORY SUBMISSION Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below